1月19日，中国证监会公布境外发行上市备案补充材料要求公示(2026年1月12日—2026年1月16日)。证 监会要求礼邦医药说明前期在江苏股权交易中心挂牌的详细情况及终止挂牌原因，是否计划继续推进A 股上市及具体安排，是否存在对本次发行上市产生重大影响的情形。据港交所2025年10月31日披露，礼 邦医药向港交所提交上市申请书，Jefferies、BofA Securities、HTSC为联席保荐人。 同时，证监会要求礼邦医药补充说明以下事项，请律师核查并出具明确的法律意见： 关于股权架构，补充说明：(1)公司历次增资及股权转让价格及定价依据，是否存在入股对价异常的情 况，是否实缴出资，是否存在利益输送，并就公司设立及历次股权变动是否合法合规出具结论性意见； (2)股权架构调整过程中历次减资的原因及对价支付情况，是否涉及虚假出资、抽逃出资，并说明相关 决策程序履行及税费缴纳情况，是否符合《公司法》和税收相关法律法规规定；(3)公司股份回购对 价、定价依据及被回购方所得税缴纳情况；(4)公司取得境内运营实体的交易对价、定价依据、支付手 段、支付期限、定价的公允性，以及上述股权转让环节相关转让方纳税申报义务履行 ...

Core Viewpoint - Dongning Bio has submitted its listing application for the third time, aiming to provide comprehensive solutions in the life sciences sector, focusing on bioprocessing and laboratory products and services [1][3]. Financial Performance - Revenue for Dongning Bio during the reporting periods (2023 to 2025) was 814.08 million yuan, 842.88 million yuan, and 657.75 million yuan, respectively, with profits of -315 million yuan, -27.5 million yuan, and 14.26 million yuan, indicating a recent turnaround to profitability [3][4]. - The bioprocessing solutions segment accounted for 77% of total revenue in 2023, with reagents and consumables being the primary revenue driver, contributing 44.1%, 47%, and 55.4% in respective periods [3][4]. Business Segments - The company operates two main business lines: bioprocessing solutions and laboratory products and services, with the former being the larger contributor to revenue [1][3]. - The overseas revenue doubled in the first three quarters of 2025, rising from 53.8 million yuan to 112.41 million yuan, increasing its share of total revenue from 9.8% to 17.1% [5][6]. Major Clients and Shareholders - WuXi Biologics, a major shareholder with a 19.75% stake, is also the largest client, contributing 14.9%, 10.9%, and 12.1% of total revenue during the reporting periods [8][10]. - Revenue from the top five clients accounted for 31.1%, 23.9%, and 32.0% of total revenue, indicating a reliance on a concentrated client base [8]. Acquisitions and Goodwill - Since 2020, Dongning Bio has acquired several companies in the bioprocessing and laboratory services sector, leading to a goodwill value of 843 million yuan as of September 30, 2025, which may face impairment risks [10][11]. - The company must estimate future cash flows from acquired subsidiaries to assess goodwill impairment, which could negatively impact financial conditions if assumptions are not met [13].

据了解，AHT-102是一款针对CLDN18.2阳性晚期实体瘤开发的Claudin18.2×CD3双特异性抗体药 物，旨在为胃癌、胰腺癌等恶性肿瘤患者提供全新的治疗选择。该药物由防城港国际医学开放试验区的 创新型药企——广西鹭港生物医药科技有限公司研发，并于2024年获国家药品监督管理局批准开展临床 试验。AHT-102是近十年来首个由广西本土企业研制的进入临床研究阶段的一类生物制品，具有里程碑 意义。此次广西完成首例给药的受试者为一名本地晚期胃癌患者，经充分知情同意和严格筛选后，由自 治区人民医院专业团队严格遵循《药物临床试验质量管理规范》（GCP）要求，顺利完成首次静脉输 注。整个给药过程平稳，患者生命体征稳定，未出现严重不良反应，后续将进入密切观察与随访阶段。 1月16日，记者从广西鹭港生物医药科技有限公司获悉，该公司自主研发的靶向治疗新药AHT-102 注射液在自治区人民医院成功完成对首例广西本地患者的临床Ⅰ期给药，该新药在全国已入组三例。这 标志着广西首个自主研制的一类生物制品正式进入临床研究阶段，实现了本土生物医药从"0"到"1"的历 史性突破。 此次首例本地患者成功给药，不仅彰显了广西本土企业在 ...

Core Insights - The announcement of the first batch of "Biomanufacturing Pilot Capability Construction Platform List" by the Ministry of Industry and Information Technology highlights Huaxi Biological Technology (Tianjin) Co., Ltd. as a leading player, achieving the highest "five-star" rating and being one of only five such units in the country [1] - The recognition emphasizes the importance of pilot platforms in bridging the gap between research and industrialization in biomanufacturing, addressing the low technology transfer rate in China compared to developed countries [1][2] Group 1: Company Achievements - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, featuring 64 pilot production lines across a 40,000 square meter facility [2] - The platform supports the scale-up of six categories of bioactive substances, serving multiple strategic emerging industries including pharmaceuticals, cosmetics, and functional foods [2][3] Group 2: Industry Context - The pilot platform is crucial for overcoming the challenges of scaling up from laboratory to industrial production, addressing issues such as process optimization, quality control, and cost accounting [2] - The Chinese government aims to cultivate over 20 biomanufacturing pilot platforms by 2027, recognizing biomanufacturing as a key aspect of the Fourth Industrial Revolution, with a projected global market size exceeding $390 billion by 2030 [3][4] Group 3: Collaborative Efforts - The pilot transformation platform is designed to be an industry-level infrastructure, providing comprehensive services to universities and startups, thus promoting the integration of government, industry, academia, research, finance, and application [4] - Huaxi Biological aims to enhance the overall capabilities of China's biomanufacturing sector through collaboration and the development of a robust platform ecosystem [4]

Group 1 - The core point of the article highlights the significant increase in the stock price of Olin Bio, which rose by 8.48% to reach 26.85 CNY per share, with a total market capitalization of 10.893 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with its main revenue sources being 90.99% from adsorbed tetanus vaccine, 4.49% from group A and C meningococcal polysaccharide conjugate vaccine, and 3.99% from type b Haemophilus influenzae conjugate vaccine [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for Huafu Fund, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund holding 600,000 shares, representing 7.56% of the fund's net value, making it the fourth-largest holding [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund has achieved a year-to-date return of 12.99% and a one-year return of 42.45%, ranking 539 out of 9009 and 2957 out of 8164 respectively [2]

Core Viewpoint - Doning Bio has submitted its prospectus to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International serving as joint sponsors [1] Group 1: Company Overview - Doning Bio operates through a dual-driven model of "bioprocess solutions" and "laboratory products and services," providing high-quality media, bioreactors, single-use products, and filters to global pharmaceutical companies, CROs/CDMOs, and research institutions [1] - The company ranks sixth among all suppliers in China's bioprocess solutions market based on 2024 revenue, and second among local suppliers [1] - Doning Bio leads in several key product categories, including cell culture media, bioreactors, single-use products, and filters among domestic enterprises [1] Group 2: Business Model and Clientele - The company supports pharmaceutical companies, CROs/CDMOs, and research institutions by offering a comprehensive range of reagents, consumables, and equipment covering all major steps of bioprocessing [1] - Doning Bio has served over 3,700 clients, with approximately 80% of major clients opting for long-term cooperation [1] Group 3: Fundraising and Future Plans - The funds raised from the IPO will primarily be used for continuous product development and enhancing the competitive advantage of comprehensive solutions [1] - The company plans to establish R&D centers, production bases, and sales networks overseas to further expand its global market share [1] - There will be an enhancement of production facilities and ongoing investment in R&D to maintain technological leadership [1]

Core Insights - The multi-valent vaccine market in China is experiencing growth, with a total of 127 batches approved in 2024, representing an 11% year-on-year increase [1] - The industry is characterized by significant advancements in technology and a shift towards multi-valent vaccines, which can prevent multiple diseases simultaneously [5][11] - Regulatory support and strategic policies are enhancing the development of the vaccine industry, emphasizing the importance of vaccine research and innovation [6] Multi-Valent Vaccine Overview - Multi-valent vaccines consist of multiple antigens to prevent various diseases, including both multi-valent and combination vaccines [3] - The market has seen a diversification of products, with several companies like Zhifei Biological and Kangtai Biological leading in the development of these vaccines [11][16] Batch Approval Data - In 2024, the approval of multi-valent vaccines included 127 batches, with specific increases in the three-valent (11%), four-valent (17%), and five-valent (10%) vaccines [1][12] - The first quarter of 2025 saw a decline in approvals, with a total of 17 batches, a 26% decrease compared to the previous year [1] Industry Development History - The Chinese vaccine industry has evolved from relying on single-valent vaccines to embracing multi-valent vaccines, marking a significant milestone in public health [5] - The introduction of the first domestically developed multi-valent vaccine by Kangtai Biological in 2011 was a pivotal moment for the industry [5] Policy Support - The Chinese government has implemented policies to support vaccine research and development, including the Vaccine Administration Law, which emphasizes the importance of vaccine innovation [6] - Recent notifications from health authorities indicate a structured approach to vaccine procurement and immunization program adjustments [6] Industry Chain - The multi-valent vaccine industry chain includes upstream raw materials, midstream research and production, and downstream sales and distribution [7] - Key players in the industry include Zhifei Biological, Kangtai Biological, and Sanofi Pasteur, which dominate the market in terms of batch approvals [16] Market Trends - Future developments in the multi-valent vaccine sector will be driven by technological innovations, including mRNA and modular vaccine designs [20] - There is a growing demand for vaccines tailored to specific demographics and health conditions, indicating a shift towards personalized healthcare solutions [21][22] - The production process is expected to become more automated and standardized, enhancing quality control and efficiency [23]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Cutia Therapeutics 科笛集團 （於開曼群島註冊成立之有限公司） （股份代號：2487） 1 CU-20101在生產工藝過程中將不使用動物源性材料，從而消除傳染性海綿狀腦病 (TSE)感染和相關過敏反應風險，預計將具有良好的安全性優勢。CU-20101將進 一步豐富本集團的皮膚產品矩陣，並有利於與本集團現有產品形成協同效應。面 向皮膚治療市場廣泛的需求，多元化產品的佈局將有望為本集團取得更大的市場 份額。 自願公告 CU-20101（注射用A型肉毒毒素）用於改善中度至重度眉間紋的 中國III期臨床試驗取得積極的頂線結果 本公告由科笛集團（「本公司」，連同其附屬公司統稱「本集團」）自願刊發，以告知 本公司股東及潛在投資者有關本集團最新業務發展資料。 本公司董事會（「董事會」）欣然宣佈，本集團CU-20101（注射用A型肉毒毒素）用 於改善中度至重度眉間紋的中國III期臨床試驗（「該臨床試驗 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 1. 根據截至2025年9月30日Spruce發行在外股份總數及全面攤薄股份計算得出。 1 （股份代號：02142） 自願公告 根據與Spruce Biosciences Inc.訂立的授權及合作協議行使認股權證 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 茲提述本公司日期為2025年2月26日的公告（「該公告」），內容有關（其中包括）本 公司孵化的創新型生物技術公司HBM Alpha Therapeutics（「HBMAT」）與Spruce Biosciences Inc.（「Spruce」）訂立授權及合作協議（「該協議」），以推進針對多種疾 病的新型促腎上腺皮質激素釋放激素(CRH)靶向療法。根據該協議，HB ...

Company Overview - Qinhau Pharmaceutical is a biopharmaceutical company focused on developing potential best-in-class targeted therapies in oncology, with a strong pipeline of innovative candidates centered around the RAS signaling pathway and synthetic lethality mechanisms [2] - The core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, having received IND approval for monotherapy in advanced solid tumors from the National Medical Products Administration (NMPA) in November 2021 [2][3] - The company has a pipeline of seven self-developed candidates, including four in clinical stages, one approved by both NMPA and FDA, and two in preclinical stages [3] Clinical Trials and Pipeline - GH21 is undergoing several clinical trials, including a Phase 1b/2 trial in combination with Gossamer and Osimertinib, with IND approvals obtained in June 2024 and November 2023 respectively [3] - GH55, another candidate targeting the RAS signaling pathway, is in a Phase 1 trial for MAPK pathway-activated solid tumors, having received IND approval in September and November 2022 [5] - The company is also developing five candidates leveraging synthetic lethality, including GH56 and GH2616, both in Phase 1 trials, and GH31, which has received IND approval [5][6] Market Potential - The global oncology drug market is projected to grow from $167 billion in 2020 to $262 billion by 2024, with a CAGR of 11.9%, and expected to reach $646 billion by 2033 [10] - The synthetic lethality drug market is anticipated to expand from $2.2 billion in 2020 to $4.2 billion by 2024, with a CAGR of 17.8%, and further increase to $17.6 billion by 2033 [19] - The SHP2 inhibitor market is expected to emerge in 2027, with projections of growth from approximately $329 million in 2029 to about $4.8 billion by 2033, reflecting a CAGR of 95.6% [13] Financial Performance - Qinhau Pharmaceutical reported revenues of approximately 4.69 million RMB for the fiscal year 2024, 3.73 million RMB for the nine months ending September 30, 2024, and 0.981 million RMB for the nine months ending September 30, 2025 [8][9] - The company incurred losses of approximately 1.52 billion RMB for the fiscal year 2024, 965.06 million RMB for the nine months ending September 30, 2024, and 988.87 million RMB for the nine months ending September 30, 2025 [8][9]